ALPHA (NCT03939026) is a phase 1 dose-escalation study for ALLO-501 (a TALEN edited allogeneic anti-CD19 CAR-T product) in relapsed/refractory B-cell lymphomas (including LBCL and FL). Here, CD19 is linked to B-cell non-Hodgkin lymphoma.